Cargando…
De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?
Autores principales: | Bomback, Andrew S., Kudose, Satoru, D’Agati, Vivette D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by the National Kidney Foundation, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230841/ https://www.ncbi.nlm.nih.gov/pubmed/34182049 http://dx.doi.org/10.1053/j.ajkd.2021.06.004 |
Ejemplares similares
-
Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine
por: D’Agati, Vivette D., et al.
Publicado: (2021) -
Amyloidogenesis: What Do We Know So Far?
por: Alraawi, Zeina, et al.
Publicado: (2022) -
Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?
por: He, Xue, et al.
Publicado: (2022) -
What we know so far
Publicado: (2021) -
Neuroproteomics in Epilepsy: What Do We Know so Far?
por: do Canto, Amanda M., et al.
Publicado: (2021)